The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.
This study is being done to see if letermovir prevents CMV reactivation in seropositive participants with a kidney or liver transplant.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
146
1 tablet by mouth, once daily, for 84 days
University of Wisconsin - Madison
Madison, Wisconsin, United States
Efficacy of letermovir as a prophylaxis of CMV
Efficacy will be measured through comparative rates of antiviral failure. Failure will be defined as withdrawal due to intolerance or breakthrough viral replication to a viral load \>1000 IU/mL.
Time frame: 84 days
Percentage of participants who develop cytomegalovirus-specific cell-mediated immunity
To be measured using the Eurofins-Viracor CMV inSIGHT™ T Cell Immunity testing. The test measures the strength of T cell responses to Cytomegalovirus (CMV) specific antigens.
Time frame: 84 days
Office of Clinical Research Department of Surgery
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.